CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Nintedanibdrug
Likely dose
Nintedanib 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02234596
NCT02234596Phase 2Completed
CompareCT.gov

Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Sep 9, 2014·Updated Jan 25, 2021

In Brief

A Phase 2 clinical trial evaluating Nintedanib for Esophagogastric Adenocarcinoma. Completed, enrolled 34 participants across 6 sites.

Detailed Summary

This is a phase II study of Nintedanib in patients with metastatic or recurrent esophagogastric cancer. The goal of the study is to evaluate the efficacy of Nintedanib, an orally available triple kinase inhibitor targeting the receptors of the vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF) receptor pathways.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophagogastric Adenocarcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 9, 2014
Enrollment StartSep 4, 2014
Primary CompletionApr 22, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 11.8 years ago

Interventions

Nintedanibdrug

Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.